Compound Monoammonium Glycyrrhizinate Injection

Glycyrrhizic acid monoamine has a strong affinity for steroid metabolic enzymes in the liver, thereby hindering the inactivation of cortisol and aldosterone. After use, it shows obvious corticosteroid-like effects, such as anti-inflammatory effects, anti-allergic effects, and protective membrane structures; there are no obvious corticosteroid-like adverse reactions. This product can promote monochrome metabolism, reduce the release of ALT and AST; induce γ-IFN and interleukin II, increase NK cell activity and OKT4/OKT8 ratio and activate the reticuloendothelial system; inhibit mast cell release of histamine; inhibit the formation of cell membrane phospholipase A2 (PL-A2) and prostaglandin E2 (PGE2) and granulomatous reactions; inhibit the production and formation of free radicals and lipid peroxides, and reduce the activity of proline hydroxylase; regulate calcium ion channels, protect lysosomal membranes and mitochondria

This product is a compound preparation, and its components are: each 1 ml contains 2 mg of monoammonium glycyrrhizinate (C42H65NO16·2H2O), 1.5 mg of L-cysteine hydrochloride (C3H7NO2S·HCl·H2O), and 20 mg of glycine (C2H5NO2).

This product is a colorless clear liquid

It is used for abnormal liver function caused by acute and chronic hepatitis; it has a certain auxiliary therapeutic effect on toxic hepatitis. It can also be used for food poisoning, drug poisoning, drug allergy, etc.

Intravenous drip. 20-80 ml at a time, add 5% glucose or 0.9% sodium chloride 250-500 ml injection solution to dilute, and slowly drip. Once a day. Intravenous injection. 20-80 ml at a time, add an equal amount of 5% glucose injection solution, and slowly push intravenously. Once a day.

Poor appetite, nausea, vomiting, abdominal distension, itchy skin, urticaria, dry mouth and edema, water and sodium retention, hypokalemia, pseudoaldosteronism, common headache, dizziness, palpitations and increased hypertension in the cardiovascular and cerebrovascular system. The above symptoms are generally mild and do not affect treatment. Occasionally, chest tightness, thirst and allergic reactions may occur.

1. Patients who are allergic to this product are prohibited from using this product. 2. Patients with severe hypokalemia and hypernatremia are prohibited from using this product. 3. Patients with hypertension and heart failure are prohibited from using this product. 4. Patients with renal failure are prohibited from using this product. 5. Patients with aldosteronism and tumors are prohibited from using this product.

Precautions for children: This experiment has not been conducted and there is no reliable reference. Precautions for pregnancy and lactation: This experiment has not been conducted and there is no reliable reference.

Hypokalemia is likely to occur when used in combination with furosemide (Lasix) or thiazide diuretics.

Keep tightly closed in a cool, dark place.

20ml: contains 40mg of monoammonium glycyrrhizinate, 30mg of cysteine hydrochloride, and 400mg of glycine

Tentative 24 months